Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
作者信息
Maeno Sayo, Koh Shizuka, Ichii Michiko, Oie Yoshinori, Nishida Kohji, Kanakura Yuzuru
机构信息
Department of Ophthalmology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Department of Innovative Visual Science, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
出版信息
Ann Hematol. 2019 Mar;98(3):793-795. doi: 10.1007/s00277-019-03614-0. Epub 2019 Jan 15.
PMID:30645676
Abstract
摘要
相似文献
1
Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.蛋白酶体抑制剂治疗后多发性骨髓瘤患者角膜晶体沉积物显著消退
Ann Hematol. 2019 Mar;98(3):793-795. doi: 10.1007/s00277-019-03614-0. Epub 2019 Jan 15.
2
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.奈非那韦-硼替佐米-地塞米松在蛋白酶体抑制剂难治性多发性骨髓瘤中显示出有前景的活性。
Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20.
3
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.基于蛋白酶体抑制剂的治疗方案用于治疗新诊断的多发性骨髓瘤。
Semin Oncol. 2017 Dec;44(6):381-384. doi: 10.1053/j.seminoncol.2018.01.002. Epub 2018 Jan 12.
4
Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients.硼替佐米和地塞米松联合作用对多发性骨髓瘤患者骨稳态的系统建模。
J Pharm Sci. 2019 Jan;108(1):732-740. doi: 10.1016/j.xphs.2018.11.024. Epub 2018 Nov 22.
5
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.伏立诺他、聚乙二醇化脂质体阿霉素和硼替佐米用于复发或难治性多发性骨髓瘤的1期研究最终结果
Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):424-432. doi: 10.1016/j.clml.2017.05.007. Epub 2017 May 10.
6
Crystalline cast nephropathy in a patient with IgD lambda myeloma.一名IgD λ型骨髓瘤患者的结晶管型肾病
Clin Exp Nephrol. 2016 Jun;20(3):491-2. doi: 10.1007/s10157-015-1187-y. Epub 2015 Oct 29.
7
Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.新型药物序贯自体造血干细胞移植对65岁及以上多发性骨髓瘤患者的影响：一项单中心回顾性分析
Bone Marrow Transplant. 2015 Nov;50(11):1486. doi: 10.1038/bmt.2015.185. Epub 2015 Aug 17.
8
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.硼替佐米治疗初诊多发性骨髓瘤患者的血浆中高糜蛋白酶样活性可预测更好的反应和更长的无进展生存期。
Ann Hematol. 2018 Oct;97(10):1879-1887. doi: 10.1007/s00277-018-3393-7. Epub 2018 Jun 26.
9
A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma.一例在接受地塞米松/硼替佐米/沙利度胺治疗骨髓瘤后发生快速进展性肾小球肾炎的独特病例。
Nephrology (Carlton). 2018 Nov;23(11):1065-1067. doi: 10.1111/nep.13249.
10
Ixazomib in the management of relapsed multiple myeloma.伊沙佐米在复发性多发性骨髓瘤中的治疗作用。
Future Oncol. 2018 Aug;14(20):2013-2020. doi: 10.2217/fon-2017-0710. Epub 2018 Feb 22.
引用本文的文献
1
Noninvasive assessment of corneal alterations associated with monoclonal gammopathy.非侵入性评估与单克隆丙种球蛋白血症相关的角膜改变。
Int J Hematol. 2019 Oct;110(4):500-505. doi: 10.1007/s12185-019-02664-4. Epub 2019 May 20.
Zotero 插件